GoodRx (GDRX) Scheduled to Post Quarterly Earnings on Thursday

GoodRx (NASDAQ:GDRX - Get Free Report) is set to announce its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of $0.09 per share for the quarter. GoodRx has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Parties that wish to register for the company's conference call can do so using this link.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.01). The company had revenue of $200.60 million for the quarter, compared to analyst estimates of $200.47 million. GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. GoodRx's quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.02 EPS. On average, analysts expect GoodRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

GoodRx Price Performance

Shares of GDRX traded down $0.26 during trading hours on Thursday, reaching $6.12. 598,339 shares of the company traded hands, compared to its average volume of 1,371,017. The stock has a market capitalization of $2.32 billion, a PE ratio of -48.08, a price-to-earnings-growth ratio of 4.17 and a beta of 1.37. The stock has a fifty day simple moving average of $7.22 and a 200 day simple moving average of $7.55. GoodRx has a fifty-two week low of $4.14 and a fifty-two week high of $9.26. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.96.

Analysts Set New Price Targets

GDRX has been the topic of several recent analyst reports. Royal Bank of Canada reissued an "outperform" rating and set a $10.00 price objective on shares of GoodRx in a research note on Friday, August 16th. UBS Group decreased their price objective on GoodRx from $9.00 to $8.50 and set a "neutral" rating on the stock in a report on Friday, August 9th. Raymond James upgraded GoodRx from an "outperform" rating to a "strong-buy" rating and set a $10.00 target price for the company in a research note on Friday, August 9th. Finally, Citigroup reduced their target price on GoodRx from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $9.36.

Insiders Place Their Bets

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 4.17% of the stock is owned by company insiders.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.